These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 18675854

  • 1. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
    Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M.
    Regul Pept; 2008 Nov 29; 151(1-3):123-9. PubMed ID: 18675854
    [Abstract] [Full Text] [Related]

  • 2. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME.
    Diabet Med; 2006 Mar 29; 23(3):240-5. PubMed ID: 16492205
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2008 May 29; 294(5):E846-52. PubMed ID: 18334612
    [Abstract] [Full Text] [Related]

  • 4. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May 29; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 5. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A.
    Horm Metab Res; 2006 Dec 29; 38(12):838-44. PubMed ID: 17163361
    [Abstract] [Full Text] [Related]

  • 6. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS.
    Horm Metab Res; 2005 Oct 29; 37(10):627-32. PubMed ID: 16278786
    [Abstract] [Full Text] [Related]

  • 7. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M.
    Clin Ther; 2009 Apr 29; 31(4):806-15. PubMed ID: 19446153
    [Abstract] [Full Text] [Related]

  • 8. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM.
    Regul Pept; 2007 Jun 07; 141(1-3):113-9. PubMed ID: 17292977
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
    Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD.
    Am J Health Syst Pharm; 2005 Jan 15; 62(2):173-81. PubMed ID: 15700891
    [Abstract] [Full Text] [Related]

  • 10. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.
    Diabetes Care; 2007 Jun 15; 30(6):1487-93. PubMed ID: 17353504
    [Abstract] [Full Text] [Related]

  • 11. Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers.
    Pinelli NR, Jantz A, Smith Z, Abouhassan A, Ayar C, Jaber NA, Clarke AW, Commissaris RL, Jaber LA.
    J Clin Pharmacol; 2011 Feb 15; 51(2):165-72. PubMed ID: 20484613
    [Abstract] [Full Text] [Related]

  • 12. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.
    Diabet Med; 2005 Apr 15; 22(4):470-6. PubMed ID: 15787675
    [Abstract] [Full Text] [Related]

  • 13. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.
    Curr Med Res Opin; 2008 Oct 15; 24(10):2943-52. PubMed ID: 18786299
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.
    Blase E, Taylor K, Gao HY, Wintle M, Fineman M.
    J Clin Pharmacol; 2005 May 15; 45(5):570-7. PubMed ID: 15831781
    [Abstract] [Full Text] [Related]

  • 15. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia.
    Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M.
    Crit Care Med; 2010 May 15; 38(5):1261-9. PubMed ID: 20228679
    [Abstract] [Full Text] [Related]

  • 16. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V, Zheng D, Stefanovski D, Bergman RN.
    Am J Physiol Endocrinol Metab; 2008 Aug 15; 295(2):E269-77. PubMed ID: 18492781
    [Abstract] [Full Text] [Related]

  • 17. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD.
    Atherosclerosis; 2010 Sep 15; 212(1):217-22. PubMed ID: 20557887
    [Abstract] [Full Text] [Related]

  • 18. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
    Hermanns N, Burkert A, Haak T.
    Exp Clin Endocrinol Diabetes; 2004 Jun 15; 112(6):310-4. PubMed ID: 15216448
    [Abstract] [Full Text] [Related]

  • 19. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
    Gredal C, Rosenfalck A, Dejgaard A, Hilsted J.
    Diabetes Res Clin Pract; 2008 May 15; 80(2):293-8. PubMed ID: 18304675
    [Abstract] [Full Text] [Related]

  • 20. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.
    Clin Ther; 2009 May 15; 31(5):980-7. PubMed ID: 19539098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.